NCT07021027 (EggsAMD) is a EARLY_PHASE1 clinical trial of Whole Egg - 4 in Intermediate Age-Related Macular Degeneration, sponsored by Kathryn Starr.

Who is sponsoring NCT07021027?

NCT07021027 is sponsored by Kathryn Starr.

What drugs are being tested in NCT07021027?

Interventions in NCT07021027: Whole Egg - 4, Whole Egg - 2.

What condition does NCT07021027 study?

NCT07021027 studies Intermediate Age-Related Macular Degeneration.

Is NCT07021027 still recruiting?

NCT07021027 is currently recruiting now. Last updated 7 January 2026.

Last reviewed 2026-01-07 · How we verify

NCT07021027: EggsAMD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eggs and Age-related Macular Degeneration (EggsAMD) Study.

Recruiting now EARLY_PHASE1 Last updated 7 January 2026

What this trial tests

EARLY_PHASE1 trial testing Whole Egg - 4 in Intermediate Age-Related Macular Degeneration in 20 participants. Currently enrolling.

Timeline

18 June 2025

Primary endpoint
30 September 2026

30 September 2026

Quick facts

Lead sponsor	Kathryn Starr
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	20
Start date	18 June 2025
Primary completion	30 September 2026
Estimated completion	30 September 2026
Sites	1 location across United States

Drugs / interventions tested

Whole Egg - 4 — full drug profile →
Whole Egg - 2 — full drug profile →

Conditions studied

Intermediate Age-Related Macular Degeneration — all drugs for Intermediate Age-Related Macular Degeneration →

Sponsor

Kathryn Starr — full company profile →

Who can join

55 and older, any sex, with Intermediate Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Age-related macular degeneration (AMD) is the primary cause of vision loss in people over the age of 55. Currently, no cure is available for individuals suffering from AMD. The purpose of this pilot study is to evaluate the feasibility of implementing a 5-month egg intervention in adults with intermediate AMD. The objective of this research study is to evaluate the feasibility of a whole egg (2 or 4 per day) intervention in older adults with intermediate AMD. The secondary objective of this research is to determine descriptive statistics, change over time and estimate effect sizes for retinal sensitivity, and vision, cognition and physical function. By completing these research objectives, the researchers hope to gain preliminary evidence in support of a larger trial that will assess the impact of egg consumption on eye health in adults with AMD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intermediate Age-Related Macular Degeneration

Currently open trials in the same condition.

NCT07189169 — QA108 Phase III Study in Subjects With Intermediate AMD · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07021027 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kathryn Starr
Last refreshed: 7 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07021027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing